Placebo-etanercept (N = 104) | Etanercept-etanercept (N = 106) | All patients (N = 210) | |
---|---|---|---|
Patients reporting an AE, n (%) | |||
Weeks 1–12 (double-blind portion) | 63 (60.6) | 71 (67.0) | 134 (63.8) |
Weeks 1–24 | 80 (76.9) | 83 (78.3) | 163 (77.6) |
Patients reporting an SAE, n (%) | |||
Weeks 1–12 (double-blind portion) | 2 (1.9) | 3 (2.8) | 5 (2.4) |
Weeks 1–24 | 3 (2.9) | 4 (3.8) | 7 (3.3) |
Patients reporting an SIE, n (%) | |||
Weeks 1–12 (double-blind portion) | 0 (0) | 0 (0) | 0 (0) |
Weeks 1–24 | 0 (0) | 1 (0.9) | 1 (0.5) |
Patients reporting an infection, n (%) | |||
Weeks 1–12 (double-blind portion) | 23 (22.1) | 30 (28.3) | 53 (25.2) |
Weeks 1–24 | 46 (44.2) | 39 (36.8) | 85 (40.5) |